$ABBV (+1,12ย %) | AbbVie Q3'24 Earnings Highlights:
๐น Adj EPS: $3.00 (Est. $2.92) ๐ข; UP +1.7% YoY
๐น Revenue: $14.46B (Est. $14.28B) ๐ข; UP +3.8% YoY
FY 2024 Guidance:
๐น Adjusted EPS: $10.90-$10.94 (Est. $10.85) ๐ก
๐น Includes unfavorable $0.64/share impact from acquired IPR&D and milestones expense
Segment Revenue:
๐ธ Immunology: $7.046B; UP +3.9% YoY
๐น Humira: $2.227B; DOWN -37.2% YoY (U.S.: -41.6%, International: -12.4%)
๐น Skyrizi: $3.205B; UP +50.8% YoY
๐น Rinvoq: $1.614B; UP +45.3% YoY
๐ธ Oncology: $1.687B; UP +11.6% YoY
๐น Imbruvica: $828M; DOWN -8.8% YoY
๐น Venclexta: $677M; UP +14.8% YoY
๐ธ Neuroscience: $2.363B; UP +15.6% YoY
๐น Botox Therapeutic: $848M; UP +13.4% YoY
๐น Vraylar: $875M; UP +16.6% YoY
๐ธ Aesthetics: $1.239B; DOWN -0.1% YoY
๐น Botox Cosmetic: $671M; UP +8.2% YoY
๐น Juvederm: $258M; DOWN -19.7% YoY
Profitability Metrics:
๐น Gross Margin: 84.4% (Adjusted)
๐น Operating Margin: 46.7% (Adjusted)
๐น Net Interest Expense: $591M
๐น Tax Rate: 16.2% (Adjusted)
Strategic Highlights:
๐ธ Cerevel Acquisition: Adds complementary neuroscience assets.
๐ธ Dividend Increase: +5.8% for 2025, effective February.
CEO Commentary:
๐ธ "Strong execution and pipeline progress give us confidence to raise our full-year guidance and dividend."